Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.72 | N/A | +4.94% |
management commentary, guidance changes, and full analysis available with Pro.
| +4.94% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on innovation and meeting consumer needs.
This earnings report indicates that Johnson & Johnson performed better than expected in terms of earnings per share. However, without revenue data and no guidance provided, investors may be cautious about the stock's future performance. The lack of a stock reaction also suggests uncertainty in the market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GRAINGER W W INC
Apr 18, 2016